Cargando…
Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position
The coronavirus disease 2019 (COVID-19) pandemic epicentre has moved to the USA and Europe, where it is placing unprecedented demands on healthcare resources and staff availability. These service constraints, coupled with concerns relating to an increased incidence and severity of COVID-19 among pat...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341025/ https://www.ncbi.nlm.nih.gov/pubmed/32641867 http://dx.doi.org/10.1038/s41416-020-0980-x |
_version_ | 1783555148174327808 |
---|---|
author | Jones, Christopher M. Radhakrishna, Ganesh Aitken, Katharine Bridgewater, John Corrie, Pippa Eatock, Martin Goody, Rebecca Ghaneh, Paula Good, James Grose, Derek Holyoake, Daniel Hunt, Arabella Jamieson, Nigel B. Palmer, Daniel H. Soonawalla, Zahir Valle, Juan W. Hawkins, Maria A. Mukherjee, Somnath |
author_facet | Jones, Christopher M. Radhakrishna, Ganesh Aitken, Katharine Bridgewater, John Corrie, Pippa Eatock, Martin Goody, Rebecca Ghaneh, Paula Good, James Grose, Derek Holyoake, Daniel Hunt, Arabella Jamieson, Nigel B. Palmer, Daniel H. Soonawalla, Zahir Valle, Juan W. Hawkins, Maria A. Mukherjee, Somnath |
author_sort | Jones, Christopher M. |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) pandemic epicentre has moved to the USA and Europe, where it is placing unprecedented demands on healthcare resources and staff availability. These service constraints, coupled with concerns relating to an increased incidence and severity of COVID-19 among patients with cancer, should lead to re-consideration of the risk–benefit balance for standard treatment pathways. This is of particular importance to pancreatic cancer, given that standard diagnostic modalities such as endoscopy may be restricted, and that disease biology precludes significant delays in treatment. In light of this, we sought consensus from UK clinicians with an interest in pancreatic cancer for management approaches that would minimise patient risk and accommodate for healthcare service restrictions. The outcomes are described here and include recommendations for treatment prioritisation, strategies to bridge to later surgical resection in resectable disease and factors that modify the risk–benefit balance for treatment in the resectable through to the metastatic settings. Priority is given to strategies that limit hospital visits, including through the use of hypofractionated precision radiotherapy and chemoradiotherapy treatment approaches. |
format | Online Article Text |
id | pubmed-7341025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-73410252020-07-08 Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position Jones, Christopher M. Radhakrishna, Ganesh Aitken, Katharine Bridgewater, John Corrie, Pippa Eatock, Martin Goody, Rebecca Ghaneh, Paula Good, James Grose, Derek Holyoake, Daniel Hunt, Arabella Jamieson, Nigel B. Palmer, Daniel H. Soonawalla, Zahir Valle, Juan W. Hawkins, Maria A. Mukherjee, Somnath Br J Cancer Consensus Statement The coronavirus disease 2019 (COVID-19) pandemic epicentre has moved to the USA and Europe, where it is placing unprecedented demands on healthcare resources and staff availability. These service constraints, coupled with concerns relating to an increased incidence and severity of COVID-19 among patients with cancer, should lead to re-consideration of the risk–benefit balance for standard treatment pathways. This is of particular importance to pancreatic cancer, given that standard diagnostic modalities such as endoscopy may be restricted, and that disease biology precludes significant delays in treatment. In light of this, we sought consensus from UK clinicians with an interest in pancreatic cancer for management approaches that would minimise patient risk and accommodate for healthcare service restrictions. The outcomes are described here and include recommendations for treatment prioritisation, strategies to bridge to later surgical resection in resectable disease and factors that modify the risk–benefit balance for treatment in the resectable through to the metastatic settings. Priority is given to strategies that limit hospital visits, including through the use of hypofractionated precision radiotherapy and chemoradiotherapy treatment approaches. Nature Publishing Group UK 2020-07-08 2020-09-01 /pmc/articles/PMC7341025/ /pubmed/32641867 http://dx.doi.org/10.1038/s41416-020-0980-x Text en © Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Consensus Statement Jones, Christopher M. Radhakrishna, Ganesh Aitken, Katharine Bridgewater, John Corrie, Pippa Eatock, Martin Goody, Rebecca Ghaneh, Paula Good, James Grose, Derek Holyoake, Daniel Hunt, Arabella Jamieson, Nigel B. Palmer, Daniel H. Soonawalla, Zahir Valle, Juan W. Hawkins, Maria A. Mukherjee, Somnath Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position |
title | Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position |
title_full | Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position |
title_fullStr | Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position |
title_full_unstemmed | Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position |
title_short | Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position |
title_sort | considerations for the treatment of pancreatic cancer during the covid-19 pandemic: the uk consensus position |
topic | Consensus Statement |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341025/ https://www.ncbi.nlm.nih.gov/pubmed/32641867 http://dx.doi.org/10.1038/s41416-020-0980-x |
work_keys_str_mv | AT joneschristopherm considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT radhakrishnaganesh considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT aitkenkatharine considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT bridgewaterjohn considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT corriepippa considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT eatockmartin considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT goodyrebecca considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT ghanehpaula considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT goodjames considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT grosederek considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT holyoakedaniel considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT huntarabella considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT jamiesonnigelb considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT palmerdanielh considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT soonawallazahir considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT vallejuanw considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT hawkinsmariaa considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition AT mukherjeesomnath considerationsforthetreatmentofpancreaticcancerduringthecovid19pandemictheukconsensusposition |